September 26, 2016 09:41 AM EDTUpdated 11:04 AM
News Briefing

Idera dumps its lead can­cer drug pro­gram; Pfiz­er won’t split up af­ter all

ENDPOINTS

Once you work through an ex­pla­na­tion of all the rea­sons Idera Phar­ma­ceu­ti­cals $IDRA has found to be op­ti­mistic about its on­go­ing Phase I/II study of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times